In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CV Therapeutics, Inc.

Latest From CV Therapeutics, Inc.

DiaSorin Strikes Dx Partnership With MeMed To Address Antibiotic Overuse

First licensing agreement for MeMed adds its immune system-based protein signature test to DiaSorin’s LIAISON test menu.

Infectious Diseases Deals

Asia Life Sciences IPO Landscape: China, Hong Kong March Ahead But Watch India

Four key Asian markets witnessed nearly 200 life science company listings over the past 10 years, with China dominating the scene and expected to stay ahead, along with Hong Kong, for the foreseeable future. But India could prove a new contender over time as firms move up the value chain, a new report shows.

Commercial Financing

Scipher Hopes IBD Alliance With Galapagos Is The First Of Many

Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.

Deals Business Strategies

CinnaGen Reports Results Of ReciGen For COVID-19

CinnaGen has revealed clinical trial results suggesting that its ReciGen interferon beta-1a product in combination with concomitant antiviral therapy can be “a new safe and effective” treatment option for COVID-19 patients, “critical for the expected second wave of the pandemic.”

Clinical Trials Coronavirus COVID-19
See All

Company Information